Course Overview

This CME conference will review new medications and therapies that are now available, or will soon be available, and discuss their comparative values. The results of trials and real world data using oral drugs to treat chronic viral hepatitis B and C, non-alcoholic fatty liver diseases, primary biliary cirrhosis, primary sclerosing cholangitis, hepatocellular carcinoma and complications of end-stage liver disease including thrombocytopenia will be reviewed in detail. New Treatments in Chronic Liver Disease is a comprehensive yet concise program for updating physicians on these and other commonly encountered problems in the treatment of liver diseases.

There was a fundamental change in the treatment of chronic hepatitis C in late 2014 with the addition of multiple new direct-acting antiviral (DAAs) drugs to current standard of care for all genotypes. There will be two separate lectures devoted to this topic this year. The first will be on currently available all-oral therapies that have been approved and are currently in use. The second will be on the benefits of cure and post-cure management of patients with cirrhosis. In addition, the pre-conference will extensively detail currently available treatment regimens with the goal of introducing the topic to new treaters.

In this past year, new treatments have been reported for both Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC). For this reason, we have invited Dr. Cynthia Levy, Assistant Director of the Schiff Center for Liver Diseases at the University of Miami, Miller School of Medicine to act as our William S. Haubrich Memorial Lecturer on these topics. The course will also review alcoholic liver disease and NASH, which have now surpassed chronic hepatitis C as the leading indications for liver transplantation in the United States. We have invited a world-recognized expert on alcoholic liver disease to update our knowledge of the topic this year.

Although hepatitis B treatments have not changed, we now have more mature data available on long-term HBsAg loss and clinical outcomes. The addition of immune-mediated therapies for HBV with the goal of curing the disease will also be included in this year’s program. New therapies for NAFLD and NASH are in development and important new data showing positive results in NASH will be presented at this meeting, including the first results of a phase 3 global treatment trial. The explosive growth of NASH in the United States has created a significant need for effective drug therapy. A number of new systemic therapies for HCC that have been approved in the last two years will also be discussed. In addition, the course will provide updates on management of hepatic encephalopathy, hyponatremia, thrombocytopenia, and complications in the transplant candidate.

Accreditation & Disclosure

Physicians
Scripps Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Scripps Health designates this live activity for a maximum of 13.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit Breakdown
Pre-Conference (Fri): 3.5
Main Conference (Sat-Sun): 10

Board of Registered Nursing
For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit(s)™ issued by organizations accredited by the ACCME. For the purpose of re-licensure, the California Board of Registered Nursing accepts AMA PRA Category 1 Credit(s)™. The majority of state boards accept AMA PRA Category 1 Credit(s)™ as meeting continuing education requirements for license renewal. Nurses should check with their state’s Board of Registered Nursing regarding use of CME credit.

American Academy of Physician Assistants
PAs may claim a maximum of 13.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME or a recognized state medical society.

Commercial Support
This course is supported, in part, by educational grants from industry, in accordance with ACCME Accreditation Standards for Commercial Support. Appropriate acknowledgment will be given to all supporters at the time of the educational activity.

Educational Objectives

After attending this live activity, participants should be able to:

- Detail the AASLD guidelines for treatment of HCV using DAAs in IFN-free regimens.
- Review our current knowledge of NAFLD and non-alcoholic steatohepatitis and explore the use of new agents and approaches to treatment of the conditions.
- Integrate the algorithm for a therapeutic approach to treatment of HBV using anti-virals.
- Discuss diagnosis, management and treatment of Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC).
- Update the skills and management required for transplant hepatology.
- Apply current options of therapy for hepatocellular carcinoma to determine the best approach for your patients.
- Describe the diagnosis and treatment of alcoholic liver disease in 2019.
- Integrate treatment options discussed for patients with ESLD due to alcohol who have complicating factors such as HCV, NASH or inherited genetic disorder.
- Discuss the issues complicating drug treatment in decompensated cirrhosis, hepatic encephalopathy and hyponatremia.
- Update the diagnosis and management of both autoimmune hepatitis (AIH) and drug-induced liver injury (DILI).
Faculty Disclosure
In accordance with the ACCME Standards for Commercial Support, course directors, planning committees, faculty and all others in control of the educational content of the CME activity must disclose all relevant financial relationships with any commercial interest that they or their spouse/partner may have had within the past 12 months. If an individual refuses to disclose relevant financial relationships, they will be disqualified from being a part of the planning and implementation of this CME activity. Owners and/or employees of a commercial interest with business lines or products relating to the content of the CME activity will not be permitted to participate in the planning or execution of any accredited activity.

A complete listing of disclosures associated with this program can be found on the conference website: www.scripps.org/Livercme and in the mobile conference app: www.grupio.com/Liver19

Pre-Conference Agenda
Friday, March 8, 2019

12:30 p.m.  Registration
1 p.m.  Welcome & Introduction
         Paul J. Pockros, MD
1:10 p.m.  Update on HCV and “Non-Invasive” Diagnostics
          Paul J. Pockros, MD
1:40 p.m.  HCV Guidelines on DAAs
          Paul J. Pockros, MD

2:40 p.m.  Break & View Exhibits
3 p.m.  Decompensated Cirrhosis and Transplant
        Catherine T. Frenette, MD
4 p.m.  Case Presentation, Discussion and Q&A
        Yuki Rosenkoetter, PAC, MPAS
5 p.m.  Adjourn
Main Conference Agenda

Saturday, March 9, 2019

7:30 a.m.  Registration, Breakfast & View Exhibits

8 a.m.  Welcome & Introduction  
Paul J. Pockros, MD

NASH, PBC, PSC AND ALD  
Moderator: Paul J. Pockros, MD

8:15 a.m.  What Has Changed in Systemic Treatment for Hepatocellular Carcinoma  
Catherine T. Frenette, MD

8:45 a.m. WILLIAM S. HAUBRICH MEMORIAL LECTURE  
Primary Biliary Cirrhosis/Primary Sclerosing Cholangitis  
Cynthia Levy, MD

9 a.m.  Alcoholic Liver Disease  
Michael R. Lucey, MD

9:45 a.m. Break & View Exhibits

10:15 a.m.  Diet and NAFLD  
Terry D. Box, MD

DEBATE  
Surgical vs. Medical Therapy for NASH  
Surgical: Michael R. Lucey, MD  
Medical: Catherine T. Frenette, MD

11:45 a.m. Lunch & View Exhibits

12:45 p.m.  Update on HCV Guidelines  
Paul Kwo, MD

1:15 p.m.  The New Epidemic on HCV  
Christian B. Ramers, MD

1:45 p.m. HCV: Benefits of Cure & Post-SVR Management  
Paul J. Pockros, MD

2:15 p.m. Break & View Exhibits

2:30 p.m. Update of HBV Guidelines  
Robert G. Gish, MD

DEBATE  
Third Trimester Prophylaxis for Hepatitis B-Is It Really Necessary for High Risk Mothers?  
Yes: Robert G. Gish, MD  
No: Paul Kwo, MD

3:30 p.m. Panel Discussion

4:30 p.m. Adjourn

Sunday, March 10, 2019

7:30 a.m. Breakfast & View Exhibits

ESLD, OLTX, HCL

8 a.m.  Both Sides of the Coin  
Terry D. Box, MD

8:30 a.m. Tips on Managing the Hospitalized Cirrhotic: Acute on Chronic Liver Failure in the Liver Transplant Candidate  
I. Raymond Thomason, MD

9 a.m. DEBATE  
Thrombopoietin Receptor Agonists vs. Platelet Infusions  
We Should Use Thrombopoietin Agonists for Our Cirrhotic Patients with Thrombocytopenia  
I. Raymond Thomason, MD  
We Should Use Platelet Infusions for Our Cirrhotic Patients with Thrombocytopenia  
Norman L. Sussman, MD

9:30 a.m. Break & View Exhibits

10 a.m. The Changing Face of Organ Allocation in Liver Transplant  
Norman L. Sussman, MD

10:30 a.m. NAFLD/NASH  
Zobair M. Younossi, MD, MPH

11 a.m. Panel Discussion

11:30 a.m. Final Adjournment

Topics, times and speakers are subject to change

Conference Highlights

• Half day pre-conference seminar reviewing the virology, genotypes and modes of infection of HCV
• Plenary talks from nationally recognized experts
• Presentations on hot topics, upcoming scientific developments, and current advances in in chronic viral hepatitis B and C, non-alcoholic fatty liver diseases, primary biliary cirrhosis, primary sclerosing cholangitis, hepatocellular carcinoma and complications of end-stage liver disease
• Networking opportunities among colleagues
• Conference app with access to course materials and recordings from the convenience of your mobile device or computer
**Conference Fees**

Space is limited so register early!

**Included:** Course tuition, access to conference materials (via mobile app and conference website) internet in meeting space, breakfast and lunch on Saturday

**Not Included:** Travel costs, lodging, parking, and dinners

### MAIN CONFERENCE

<table>
<thead>
<tr>
<th></th>
<th>Thru Jan 31</th>
<th>Feb 1 - Mar 4</th>
<th>On-site after Mar 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians</td>
<td>$350</td>
<td>$375</td>
<td>$400</td>
</tr>
<tr>
<td>RN, PA, NP</td>
<td>$280</td>
<td>$305</td>
<td>$330</td>
</tr>
<tr>
<td>Fellows and Residents</td>
<td>$175</td>
<td>$200</td>
<td>$225</td>
</tr>
</tbody>
</table>

### PRE-CONFERENCE

<table>
<thead>
<tr>
<th></th>
<th>Thru Jan 31</th>
<th>Feb 1 - Mar 4</th>
<th>On-site after Mar 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-Conference</td>
<td>$100</td>
<td>$125</td>
<td>$150</td>
</tr>
</tbody>
</table>

**Attendance Policies**

**Attendee Cancellation, Substitution, Refund**

The course tuition is refundable, minus a $100 processing fee (MD, RN, PA, NP) or a $50 processing fee (Fellows, Residents) and $20 processing fee for the pre-conference if your cancellation is received in writing no later than **Monday, February 25, 2019**. Attendee substitutions are allowed, but notification must be made in writing by **Monday, February 25, 2019**. After this date, under no circumstances will refunds, credits, or substitutions be granted. No refunds or credits will be given to “no shows.”

**Guest Attendance Policy**

All conference activities, including meal functions, are exclusively reserved for paid conference attendees. Children and family members are not allowed in the conference areas. Badges provided at registration are required for entrance into all functions and will be strictly enforced.

**Scripps Conference Modification or Cancellation**

Scripps reserves the right to modify the course’s schedule or program as necessary. Scripps also reserves the right to cancel this conference, in which case a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of Scripps cancellation.

**Recording and Photography Clause**

Scripps reserves rights to record (audio and video) and/or photograph all conference proceedings for in marketing materials, presentations and course content sales.

---

**Conference Location**

**Estancia La Jolla Hotel**

9700 N. Torrey Pines Road  
La Jolla, California 92037  
855-318-7602  
estancialajolla.com

**Rates & Reservations**

Make your reservations early! A block of rooms is being held for us until **February 14, 2019** or until the block fills, whichever comes first. After this date, reservations will be accepted on a space and rate availability basis only. Be sure to mention you are with the Scripps Liver Disease conference to receive the reduced rate of **$245** per night.

Please note: Attendees who book their room through an online, third-party service (Hotels.com©, Expedia.com©, Priceline.com©, etc.) are not eligible to receive the amenities listed above.

---

**Download the Scripps CME App for your smart phone or tablet!**

All conference information including a detailed agenda, faculty listing, faculty disclosures, industry support, attendee list, and course materials can be found on the free Scripps CME conference app for smart phones, tablets and laptop computers. To download the app on your smart phone or other device visit the appropriate app store and search ScrippsCME (must be one word). The app is free of charge and will be continuously updated during and after the course.

To access the site using a web browser: [http://www.grupio.com/Liver19](http://www.grupio.com/Liver19)
New Treatments in Chronic Liver Disease

Target Audience
- Hepatologists
- Gastroenterologists
- Infectious Disease Specialists
- Nurse Practitioners
- Physician Assistants
- Nurses
- Residents/Fellows